Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | CCKAR | P32238 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23706773 | 0.98 | ATM (0.40) | MEN1KMT2AKDM4EPOLBATM | |
| SCHEMBL25480713 | 0.84 | MEN1 (0.44) | MEN1KMT2AKDM4EPOLBATM | |
| SCHEMBL23706758 | 0.82 | L3MBTL1 (0.37) | MEN1KMT2AKDM4EALDH1A1DRD4 | |
| SCHEMBL20763691 | 0.82 | KDM4E (0.41) | MEN1KMT2AKDM4EPOLBMAPT | |
| SCHEMBL11911641 | 0.81 | MEN1 (0.43) | MEN1KMT2AKDM4EPOLBATM | |
| SCHEMBL23706755 | 0.80 | SMN1; SMN2 (0.45) | MEN1KMT2AKDM4EPOLBALDH1A1 | |
| SCHEMBL12083728 | 0.80 | USP2 (0.45) | KDM4EPOLBCYP2D6ALDH1A1TDP1 | |
| SCHEMBL23706764 | 0.79 | KMT2A (0.44) | MEN1KMT2AALDH1A1TSHRDRD4 | |
| SCHEMBL12349177 | 0.79 | POLB (0.40) | MEN1KMT2AKDM4EPOLBATM | |
| SCHEMBL25135334 | 0.79 | DRD2 (0.37) | MEN1KMT2ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262589-A1 | AMINE COMPOSITION FOR CARBON DIOXIDE SEPARATION USE | TOSOH CORPORATION (JP) | 2025-08-21 | — | — | US | disclosed |
| EP-4494740-A1 | AMINE COMPOSITION FOR CARBON DIOXIDE SEPARATION USE | TOSOH CORPORATION (JP) | 2025-01-22 | — | — | EP | disclosed |
| WO-2023204222-A1 | AMINE COMPOSITION FOR CARBON DIOXIDE SEPARATION USE | 東ソー株式会社 | 2023-10-26 | — | — | WO | disclosed |
| CN-114901383-A | Composition for separating carbon dioxide and method for separating carbon dioxide | 东曹株式会社 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021153650-A1 | COMPOSITION FOR CARBON DIOXIDE SEPARATION AND METHOD FOR SEPARATING CARBON DIOXIDE | 東ソー株式会社 | 2021-08-05 | — | — | WO | disclosed |
| EP-1569937-B1 | C-6 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL MYERS SQUIBB CO (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-17 | — | — | US | disclosed |
| US-7846931-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2058314-A1 | Pyrrolotriazine compounds as kinase inhibitors | Bristol-Myers Squibb Company (US) | 2009-05-13 | — | — | EP | disclosed |
| EP-1699798-A4 | DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2009-03-11 | — | — | EP | disclosed |
| US-7064203-B2 | Di-substituted pyrrolotriazine compounds | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-06-20 | — | — | US | disclosed |
| US-20050222153-A1 | C-6 modified indazolylpyrrolotriazines | VITE GREGORY D | 2005-10-06 | — | — | US | disclosed |
| US-20050197339-A1 | Di-substituted pyrrolotrizine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| EP-1569937-A2 | C-6 MODIFIED INDAZOLYLPYRROLOTRIAZINES | Bristol-Myers Squibb Company (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20050182058-A1 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-18 | — | — | US | disclosed |
| WO-2005066176-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005065266-A2 | DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| US-6916815-B2 | C-6 modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-12 | — | — | US | disclosed |
| US-20040142931-A1 | C-6 modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004054514-A2 | C-6 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | MEN1 3024/4885KMT2A 1682/4885KDM4E 2206/4885 |
| US-20050222153-A1 | C-6 modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | MEN1 2849/4885KMT2A 2678/4885KDM4E 2779/4885 |
| US-20050197339-A1 | Di-substituted pyrrolotrizine compounds | ERBB2, ERBB4, EGFR | MEN1 2876/4885KMT2A 1877/4885KDM4E 1487/4885 |
| US-20050182058-A1 | Pyrrolotriazine compounds as kinase inhibitors | ERBB2, ERBB4, ERBB3 | MEN1 3024/4885KMT2A 1682/4885KDM4E 2206/4885 |
| US-20040142931-A1 | C-6 modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | MEN1 2283/4885KMT2A 2696/4885KDM4E 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.